
Shareholder advisory firm Glass Lewis on Friday recommended Spirit Airlines investors approve Frontier $2.9 billion takeover bid, saying it was the “best available” at this time.
The report, which helps guide investors on how to vote on the proposed merger, comes only hours after Frontier said it agreed to a break-up fee as part of a revised deal the companies hope Spirit shareholders will support.
“We believe the Frontier Merger Consideration provides Spirit shareholders with a fairly compelling valuation and premium for their Spirit shares, on balance,” the report said, adding Glass Lewis believed the revised deal terms should offer “added protection” against potential regulatory risk.
Glass Lewis’ report was published days after its larger rival Institutional Shareholders Services urged Spirit shareholders to vote against the deal because Spirit had failed to negotiate a break-up fee.
JetBlue Airways is trying to muscle in on the deal with a hostile $3.3 billion offer that Spirit has rejected.
Glass Lewis wrote that JetBlue had not made a “sufficiently compelling case to warrant overriding the board’s determination” and that the Frontier offer would have an easier path to closing than the JetBlue offer.
JetBlue said it disagrees with the Glass Lewis recommendation and said the conclusion “rests on a remarkably superficial regulatory analysis.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas